Androgenetic Alopecia
Conditions
Keywords
Finasteride topical, Minoxidil topical, Male androgenetic alopecia
Brief summary
A double-blind, randomized, controlled trial of 40 male patients with androgenetic alopecia was conducted. All subject were randomized to receive either combination of minoxidil 5% topical and finasteride 0,1% topical or minoxidil 5% topical
Detailed description
All subject were randomized to receive either combination of minoxidil 5% topical and finasteride 0,1% topical or minoxidil 5% topical The primary outcome was increase of the hair density and hair diameter (mean thickness) measured by trichoscan Measurements were done at baseline and every four weeks for twelve weeks. Additionally, side effects of therapy was also measured.
Interventions
DRUGFinasteride
finasteride topical 0,1%
DRUGMinoxidil
minoxidil topical 5%
Sponsors
Indonesia University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Triple (Participant, Investigator, Outcomes Assessor) The allocation sequence was generated with a computer by an analyst. The allocation sequence was concealed from the investigators, outcomes assessor, and subjects.
Intervention model description
Eligible subjects were randomized to receive either combination of minoxidil 5% topical and finasteride 0,1% topical or minoxidil 5% topical. The allocation sequence was generated with a computer by an analyst.
Eligibility
Sex/Gender
MALE
Age
18 Years to 59 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male aged from 18-59 years diagnosed with androgenic alopecia 2. Androgenic alopecia type III-V according to Hamilton-Norwood criteria 3. Willing to participate in this research by signing the consent form after receiving an explanation from the researcher 4. Willing to not cutting the hair nor coloring the hair during the study
Exclusion criteria
1. Diagnosed with other infectious or inflammatory skin disease in the scalp 2. Using oral medications or vitamins that aim to increase the amount of hair in the last 1 month 3. Using topical medication that aim to increase the amount of hair in the last 2 weeks 4. Undergoing cosmetic procedure for AGA therapy such as low-level laser therapy (LLLT) procedures, platelet-rich plasma (PRP) injections, or microneedling within the last 3 months 5. Have sexual disorder such as decreased libido 6. Have a history of allergy or irritant contact dermatitis to the minoxidil and finasteride
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hair density | 4 times of measurement in 3 months | Density of the hair is the number of hair strands per square inch of the scalp measured by trichoscan |
| Hair diameter (mean thickness) | 4 times of measurement in 3 months | Hair diameter is the midline of the hair shaft measured by trichoscan |
| Side effects | 4 times of measurement in 3 months | Incidence of side effects |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Terminal hair percentage (hair rate terminal) | 4 times of measurement in 3 months | Terminal hair is a hair that has a hair more than 60 micrometer, contains the medulla and can be up to 100 cm in length measured by trichoscan |
| Dermoscopy | 4 times of measurement in 3 months | Dermoscopy is a non-invasive technique that allows more detailed examination of the scalp and hair shaft under magnification |
| Velus hair percentage ( hair rate vellus) | 4 times of measurement in 3 months | Vellus hair is a hair that is less than 30 micrometer in diameter, lacks a medulla hair, and is 2 cm in length measured by trichoscan |
Countries
Indonesia
Contacts
Primary ContactFarah F Lubis, MD
Outcome results
None listed